BRIEF-Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis

Reuters11-21

BRIEF-Contineum <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis

Nov 20 (Reuters) - Contineum Therapeutics Inc CTNM.O:

CONTINEUM THERAPEUTICS REPORTS TOPLINE DATA FROM ITS PHASE 2 PIPE-307 VISTA TRIAL FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
CONTINEUM THERAPEUTICS INC - TRIAL DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTS
CONTINEUM THERAPEUTICS INC - PIPE-307 SHOWS NO SIGNIFICANT CHANGE IN LCLA
CONTINEUM THERAPEUTICS INC - PIPE-307 SHOWS ACCEPTABLE SAFETY AND TOLERABILITY

Source text: ID:nBw6GBK72a

Further company coverage: CTNM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585168593?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 05:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585168593","market":"us","top_or_hot":-1,"title":"BRIEF-Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Contineum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis </title></head><body><p><span>Nov 20 (Reuters)</span><span> - </span>Contineum Therapeutics Inc <span>CTNM.O</span>:</p><ul><li><p>CONTINEUM THERAPEUTICS REPORTS TOPLINE DATA FROM ITS PHASE 2 PIPE-307 VISTA TRIAL FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)</p></li><li><p>CONTINEUM THERAPEUTICS INC - TRIAL DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTS</p></li><li><p>CONTINEUM THERAPEUTICS INC - PIPE-307 SHOWS NO SIGNIFICANT CHANGE IN LCLA</p></li><li><p>CONTINEUM THERAPEUTICS INC - PIPE-307 SHOWS ACCEPTABLE SAFETY AND TOLERABILITY</p></li></ul><p>Source text: <span>ID:nBw6GBK72a</span></p><p>Further company coverage: <span>CTNM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-21 05:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Contineum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis </title></head><body><p><span>Nov 20 (Reuters)</span><span> - </span>Contineum Therapeutics Inc <span>CTNM.O</span>:</p><ul><li><p>CONTINEUM THERAPEUTICS REPORTS TOPLINE DATA FROM ITS PHASE 2 PIPE-307 VISTA TRIAL FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)</p></li><li><p>CONTINEUM THERAPEUTICS INC - TRIAL DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTS</p></li><li><p>CONTINEUM THERAPEUTICS INC - PIPE-307 SHOWS NO SIGNIFICANT CHANGE IN LCLA</p></li><li><p>CONTINEUM THERAPEUTICS INC - PIPE-307 SHOWS ACCEPTABLE SAFETY AND TOLERABILITY</p></li></ul><p>Source text: <span>ID:nBw6GBK72a</span></p><p>Further company coverage: <span>CTNM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTNM","symbol_name":"Contineum Therapeutics, INC.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA6PCSB0:1","article_id":"2585168593","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585168593","pubTimestamp":1763674984,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis Nov 20 (Reuters) - Contineum Therapeutics Inc CTNM.O","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTNM":"Contineum Therapeutics, INC.","BK4007":"制药"},"translate_title":"BRIEF-Contineum Therapeutics报告其治疗复发缓解型多发性硬化症的2期Pipe-307 Vista试验的顶线数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTNM":0.9},"content_text":"BRIEF-Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis Nov 20 (Reuters) - Contineum Therapeutics Inc CTNM.O:CONTINEUM THERAPEUTICS REPORTS TOPLINE DATA FROM ITS PHASE 2 PIPE-307 VISTA TRIAL FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)CONTINEUM THERAPEUTICS INC - TRIAL DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTSCONTINEUM THERAPEUTICS INC - PIPE-307 SHOWS NO SIGNIFICANT CHANGE IN LCLACONTINEUM THERAPEUTICS INC - PIPE-307 SHOWS ACCEPTABLE SAFETY AND TOLERABILITYSource text: ID:nBw6GBK72aFurther company coverage: CTNM.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585168593","isCrawlerRequest":true}